Panel Discussion: Practice Changing Developments in Benign and Malignant Hematology
By: Joseph Tuscano, MD
Indentification and Management of Tyrosine Kinase Inhibitors (TKIs) Toxicities
By: Josephine Previlon, MPAS, PA-C
New Agents and New Toxicities in Malignant Hematology: BCL2 Inhibitors, Anti-BCMA, and FLT3 Inhibitors
By: Nicole Ianniello, PharmD
Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions
By: Rami Komrokji, MD
Myelodysplastic Syndrome: Challenges, Current Standard Therapy and Future Directions
By: Rami Komrokji, MD
B-Cell NHL and Hodgkin’s Disease Biologicals, Checkpoint Inhibitors, CAR-T cells
By: Eduardo M. Sotomayor, MD
How to Decide which Frontline Therapy in MM After First Relapse Post-Transplant
By: Melissa Alsina, MD
